Published Date : Jun 30, 2014
United States Food and Drug Administration (USFDA) approved a second drug for the treatment of methicillin-resistant Staphylococcus aureus (MRSA), during its new fast-track incentive program. This new antibiotic is one of the first to be released under the scheme known as Dalvance.
This new antibiotic is an intravenous drug. It can be used to treat soft tissue and skin infections. This new scheme is aimed towards treating acute bacterial skin and skin structure infections. The news of this second drug was released during the end of this month. The drug is known by the name of tedizolid phosphate or Sivextro.
This new drug is an antibiotic which can be used orally or by intravenous means to treat severe MRSA infection. The US News and Health Report stated that this medicine has been clinically tested on more than 1,300 adults who had serious skin infections.
During the studies, Sivextro was found to be much more effective than linezolid. Linezolid is an antibiotic which is currently used to treat a similar disorder and works similar to Sivextro. Both these antibiotics have been developed under the new Generating Antibiotic Incentives Now program by FDA. This program offers incentives like extended exclusivity to many manufacturers of upcoming antibiotics.
Under this scheme of USFDA there are two more antibiotics which will be released soon. The manufacturers of Sivextro have also reported that FDA is reviewing ceftozolone which is an antibiotic candidate for treating complicated urinary tract related infections.